FAQ on Soligenix Inc.'s HyBryte(TM) Positive Data and Advancement in CTCL Treatment

What is HyBryte(TM) and what is it used for?

HyBryte(TM) (synthetic hypericin) is a novel photodynamic therapy developed by Soligenix Inc. for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and difficult to treat orphan disease.

Why is the advancement of HyBryte(TM) significant?

The advancement is significant because CTCL is an area of unmet medical need with very limited safe and effective therapies, and HyBryte(TM) has shown promising results in improving patient outcomes with a faster treatment response compared to other therapies.

How does HyBryte(TM) compare to other CTCL treatments?

HyBryte(TM) has demonstrated a strong treatment response by week 18, which is noticeably faster than other therapies that may take six to 12 months to show improvement, offering a potential advantage in treatment efficacy and patient quality of life.

Who is involved in the ongoing study of HyBryte(TM)?

The ongoing open-label, investigator-initiated study (IIS) is being conducted by Soligenix Inc., with Dr. Kim playing a key role, and involves patients with early-stage CTCL.

When can we expect more updates on the HyBryte(TM) study?

Soligenix Inc. plans to provide additional updates on the IIS as data becomes available, though specific timelines were not mentioned in the press release.

Where can I find more information about Soligenix Inc. and HyBryte(TM)?

More information can be found on Soligenix’s website here and the full press release here.

What are the next steps for HyBryte(TM) following these study results?

Following these positive interim results, Soligenix Inc. is advancing enrollment in the confirmatory Phase 3 FLASH 2 replication study and plans to seek regulatory approvals to support potential commercialization of HyBryte(TM) worldwide.

Who should be contacted for more information about HyBryte(TM)?

For more information, interested parties can reach out to Soligenix Inc. directly, though specific contact details were not provided in the press release.